At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,004 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Atezolizumab 1200 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
In Brief
A Phase 3 clinical trial evaluating Atezolizumab for Urinary Tract Cancer. Completed, enrolled 1,004 participants across 175 sites in 32 countries.
Detailed Summary
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Cancer
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, Germany, Greece, Hungary, India, Ireland, Italy, Lebanon, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Saudi Arabia, Slovakia, Spain, Switzerland, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2016
Primary CompletionDec 2022
TodayJul 2026
First PostedOct 10, 2016
Enrollment StartNov 30, 2016
Primary CompletionDec 12, 2022
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 9.7 years ago
Interventions
Atezolizumabdrug
Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.